Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • joefish123456 joefish123456 May 14, 2013 7:52 PM Flag

    to funny when you think about it

    you had enron ceo telling it workers to buy more while the ship was burning.... then you have orwin ceo affy saying the drug doesn't work when it works on 99.98% of people.epogen is no better then omontys it had problems to smells fish to me

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So you say Epogen is no better than Omontys. Your post smells like fish to me. Let's see what others have to say about Epogen compared to Omontys, from a NY Times article published shortly after the Omontys recall:

      Dr. Daniel W. Coyne, a kidney specialist at Washington University in St. Louis, said that unless the problem was because of contamination, “this could easily lead to withdrawal of drug approval.” He said that “two in 10,000 deaths on first exposure is unacceptable, compared to nothing like this” with Epogen.

      Dr. Ajay K. Singh, a kidney specialist at Brigham and Women’s Hospital in Boston, said that the recall should result in “minimal disruption” because centers could use Epogen or another Amgen drug, Aranesp. But he said it might be hard for Affymax and Takeda, which is based in Osaka, to show the safety of their drug without a huge study.

      • 1 Reply to godwinpeak
      • this is treated for Chronic Kidney Dialysis patients, that means they are very fragile patients.

        AMGN / J&J's ARNESP & EPOGEN both are not that great too. There are lots of deaths reported with that too.

        OMONTYS was voluntarily recalled, FDA did not force AFFY to withdraw the drug, they should have continued with this drug.

        We will wait for the resolution, that is where the Opportunity lies!

        I said it is either the product is coming back to the market or not.

        You hold your position NOT coming, I/ we longs and so many funds hold shares with a POSITIVE EXPECTED OUTCOME AND RELAUNCH of the drug.

        Your other attempts like BK, the WEBSITE issue are all simply baloney, it is proven.

        As for as Europeon approval it is the same FDA approved one. For elderly CKD patient population.

        No trials, you are misleading more and more and desperate you are!

        Sentiment: Hold

 
AFFY
0.1051-0.0079(-6.99%)May 27 11:49 AMEDT